Biotech venture capital firm Ysios Capital said today it has raised $140 million (€126.4 million) for its 2nd life science fund, Ysios BioFund II Innvierte. The closing exceeded its initial target of $110 million (€100 million), the VC shop said. The Spanish firm said it plans to finance up to 15 biotech, medtech and diagnostic […]
European venture capital firm Ysios Capital is looking to raise some $137.8 million (€100 million) in support of its lifesciences investment activities.
Ysios plans to use funds from the investment pool, which the company calls its BioFund II, to support up to 15 lifesciences companies with disruptive potential. The company in 2008 raised about $95 million (€69 million) for its BioFund I, according to a press release.
CVRx said it added $12 million from DaVita HealthCare, Ysios Capital and others to its Series F funding round, taking the total for the round to $42 million.
The Minneapolis-based company is planning to use the money to advance clinical trials and expand its international commercial footprint, according to a press release. CVRx developed the Barostim Neo, a pacemaker-like device designed to treat hypertension.